Protocol No.: EA9171

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Principal Investigator
Ross, Kelly
Phase
II
Age Group
Adult
Applicable Disease Sites
Leukemia
Multiple Myeloma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov